Loading stock data…
$6.41-0.61 (-8.69%)
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers.
Olema Pharmaceuticals, Inc. in the Healthcare sector is trading at $6.41 with a market capitalization of $961M. Wall Street consensus targets $36.50 (10 analysts), implying a +469.4% move over the next 12 months. The stock is currently near its 52-week low of $6.24, remaining 55.9% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 23 is oversold, raising the odds of a near-term bounce. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$67.18M↓ | -$57.99M↓ | -$50.08M↓ | -$45.88M↑ | -$47.86M |
| Net Income | -$63.20M↓ | -$53.09M↓ | -$46.06M↓ | -$42.22M↑ | -$43.78M |
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) an...